DAC vs no-DAC (Mod GRF 1-29) — dose ranges, reconstitution, Ipamorelin stacking, cycling and safety. For research purposes only — not for human use.
Clean Peptides does not provide advice on dosages or usage. This guide compiles product information from Clean Peptides together with independent educational material from PeptideWiki, for research reference only. It is not medical advice and does not represent recommendations, endorsements, or instructions from Clean Peptides.
What Is CJC-1295?
CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) — the first 29 amino acids of GHRH with substitutions for enzymatic stability. It stimulates the pituitary to release endogenous GH. It exists in two fundamentally different versions that are NOT interchangeable.
| Feature | No-DAC (Mod GRF 1-29) | With DAC |
|---|---|---|
| Half-life | ~30 minutes | 6–8 days |
| GH Release | Sharp, pulsatile | Sustained “bleed” |
| Injection Frequency | 2–3x per day | 1–2x per week |
| Typical Dose | 100 mcg per injection | 2 mg per injection |
| Pairs with GHRPs | Yes (e.g. + Ipamorelin) | Not recommended |
| Fasting Required | Yes (2 h before, 30 min after) | Less critical |
Dosing derives from clinical PK data, GH response studies and community experience.
How Dosage Is Determined
DAC studied by ConjuChem: 30–60 mcg/kg weekly produced sustained GH elevation, IGF-1 up 1.5–3×. No-DAC (Mod GRF 1-29) half-life ~30 min; 1–2 mcg/kg produces a sharp GH pulse; GHRH receptor saturates above ~150 mcg. Community standard: no-DAC 100 mcg 2–3x daily (with Ipamorelin); DAC 2 mg 1–2x weekly. Strength of evidence: moderate.
No-DAC (Mod GRF 1-29) Dosage Ranges
| Level | Dose/Injection | Frequency | Daily Total | Notes |
|---|---|---|---|---|
| Beginner | 100 mcg | 2x/day | 200 mcg | Pre-bed + morning fasted |
| Intermediate | 100 mcg | 3x/day | 300 mcg | Morning, post-workout, pre-bed |
| Advanced | 100–150 mcg | 3x/day | 300–450 mcg | Diminishing returns above 100 |
Most users dose 100 mcg regardless of body weight (receptor saturation).
DAC Dosage Ranges
| Level | Dose/Injection | Frequency | Weekly Total | Notes |
|---|---|---|---|---|
| Beginner | 2 mg | Once/week | 2 mg | Same day each week |
| Intermediate | 2 mg | Twice/week | 4 mg | e.g. Monday and Thursday |
| Advanced | 2–3 mg | Twice/week | 4–6 mg | Monitor blood work closely |
Reconstitution & Dosing (with the supplied 3 mL)
At Clean Peptides, CJC-1295 (no DAC) is supplied in a combination vial with Ipamorelin — 5 mg CJC-1295 + 5 mg Ipamorelin in one vial. Both peptides share the vial, so a single draw delivers an equal amount of each. Reconstitute with the full 3 mL of bacteriostatic water supplied. On a U-100 insulin syringe, 100 units = 1 mL.
After 3 mL the concentration is 1.67 mg/mL of each peptide — about 16.7 mcg per insulin unit, of each.
How to reconstitute
- Wash your hands and lay out the vial, the 3 mL bacteriostatic water, an insulin syringe and alcohol swabs.
- Flip off the caps and swab both stoppers; air-dry 10–15 seconds.
- Draw the full 3 mL of bacteriostatic water.
- Add it slowly down the inside glass wall — never onto the powder cake.
- Dissolve gently — let it sit 1–2 minutes, then swirl until clear. Never shake.
- Label and refrigerate at 2–8 °C; use within 28–30 days.
Draw volumes with 3 mL — Ipamorelin + CJC-1295 combo vial
Because both peptides sit at 1.67 mg/mL, each unit drawn delivers ~16.7 mcg of both at once:
| Units drawn | CJC-1295 (no DAC) | Ipamorelin | Notes |
|---|---|---|---|
| 6 u | 100 mcg | 100 mcg | Standard per-dose stack |
| 9 u | 150 mcg | 150 mcg | — |
| 12 u | 200 mcg | 200 mcg | Higher per-dose |
| 18 u | 300 mcg | 300 mcg | Upper range |
Typical protocol: 6 units (100 mcg + 100 mcg), 2–3× per day, fasted. The combo vial provides roughly 50 such doses of each peptide.
Standalone or DAC versions: the figures above are for the Clean Peptides combo vial. For any standalone vial, use the same rule — units = dose (mg) × 300 ÷ vial strength (mg) with the 3 mL. CJC-1295 with DAC is a different long-acting version dosed ~2 mg once or twice weekly (see the DAC ranges above), and is not mixed with a daily GHRP.
Dosage by Goal
- General GH optimization: 100 mcg CJC no-DAC + 100 mcg Ipamorelin, 2–3x/day; 8–12 wk on, 4 wk off.
- Fat loss: 100 mcg + 100 mcg Ipamorelin, 3x/day (fasted); 12 wk on, 4 wk off.
- Anti-aging & convenience (DAC): 2 mg DAC 1–2x/week, alone (no daily GHRP).
- Injury recovery (triple stack): CJC no-DAC + Ipamorelin + BPC-157 250–500 mcg 2x/day near injury.
- Muscle growth: 100 mcg + 100 mcg Ipamorelin, 3x/day; 12 wk on, 4 wk off.
For most goals, CJC no-DAC + Ipamorelin is the recommended starting stack.
Injection Guide
- Wash hands; prepare a clean workspace.
- Swab the vial stopper and injection site; air-dry.
- Draw the peptide (combine with Ipamorelin in one syringe if stacking).
- Remove air bubbles.
- Pinch skin (abdomen or outer thigh); insert at 45–90°.
- Inject slowly; wait 5 s; withdraw.
- Dispose in a sharps container; rotate sites.
Mixing no-DAC + Ipamorelin: draw CJC first, then Ipamorelin into the same syringe at injection time. Do NOT pre-mix in a single vial. Do NOT mix DAC with Ipamorelin.
Cycle Duration & Timing
No-DAC: 8–12 wk on, 4 wk off (standard); or 5-on/2-off weekly. DAC: 8–12 wk on, 4–8 wk off.
No-DAC timing: morning fasted, post-workout, pre-bed (2 h after last meal — highest priority). DAC timing: same day(s) each week; time of day less critical.
Stacking Protocols
CJC-1295 no-DAC + Ipamorelin (“The Gold Standard”): 100 mcg each, 2–3x/day, fasted. Synergistic GH release 2–3× either alone with minimal side effects.
Full Ipamorelin protocols: see our Ipamorelin Dosage Guide.
Other stacks: + BPC-157 (recovery); + Sermorelin 100–200 mcg pre-bed (enhanced GHRH — less validated).
Safety, Side Effects & Contraindications
Common (both versions): mild flushing/warmth, headache, injection-site irritation, increased hunger, vivid dreams, mild water retention. DAC-specific: more pronounced water retention, joint stiffness, carpal-tunnel-like symptoms, greater insulin resistance.
Contraindications: active cancer or history of cancer; diabetic retinopathy; pregnancy/breastfeeding; active pituitary tumors; uncontrolled diabetes; under 25 years old.
Monitor: IGF-1, fasting glucose & HbA1c, comprehensive metabolic panel, TSH/Free T4. Baseline + 6–8 weeks. Not FDA-approved; WADA-banned.
Common Mistakes
- Confusing DAC and no-DAC (different half-lives and protocols).
- Using DAC with daily Ipamorelin.
- Injecting no-DAC after eating.
- Overdosing no-DAC above 150 mcg (receptor saturation).
- Underdosing DAC below 1 mg/week.
- Using both DAC and no-DAC simultaneously.
- Not cycling; injecting no-DAC only once per day.
Key Takeaways
- Two versions: no-DAC (~30 min half-life) and DAC (6–8 day half-life) — NOT interchangeable.
- No-DAC: 100 mcg SubQ 2–3x/day, fasted, almost always with Ipamorelin.
- DAC: 2 mg 1–2x/week, alone.
- Gold-standard stack: CJC no-DAC + Ipamorelin. Cycle 8–12 wk on / 4 wk off.
- Not FDA-approved; banned by WADA.
Download & Related Resources
Shop the combo: Ipamorelin + CJC-1295 Combo
Related guides: Ipamorelin Dosage Guide · BPC-157 Dosage Guide
References
- Teichman SL, et al. “Prolonged stimulation of GH and IGF-1 by CJC-1295.” J Clin Endocrinol Metab. 2006;91(3):799-805.
- Ionescu M, et al. “Pulsatile GH secretion persists during continuous stimulation by CJC-1295.” J Clin Endocrinol Metab. 2006;91(12):4792-4797.
- Alba M, et al. “Once-daily CJC-1295 normalizes growth in the GHRH knockout mouse.” Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
- Sackmann-Sala L, et al. “Pharmacological and physiological aspects of GH releasing peptides.” Endocr Dev. 2010;17:22-35.
- Veldhuis JD, et al. “Mechanisms and regulators of growth hormone secretion.” Endocrinol Metab Clin North Am. 2007;36(1):75-100.
For research purposes only — not for human use. Educational reference compiled from PeptideWiki (peptidewiki.co).
